Project Grant R21DE034560
Award Date 8/20/25
Completion Date 7/31/27
Dollars Obligated $433K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This federal Project Grant award of $315,000 was provided by the National Institute of Dental and Craniofacial Research (NIDCR), which administers the Oral Diseases and Disorders Research grant program (CFDA 93.121). The funding will support research at The Ohio State University to develop novel antibody therapeutics that target human papillomavirus (HPV) oncoproteins, which are the major drivers of head and neck cancers. The research aims to generate HPV-specific human monoclonal antibodies and...
- This $642,488 Project Grant was awarded on June 10, 2025 by the National Institute of Dental and Craniofacial Research (NIDCR) under the federal Oral Diseases and Disorders Research program (CFDA 93.121). The grant supports research conducted by a collaborative partnership between Henry Ford Health and Michigan State University Health Sciences to investigate mechanisms by which human papillomavirus (HPV) drives immune evasion in head and neck squamous cell carcinomas (HNSCC). The research aims...
- The Project Grant award titled "DECIPHERING THE MECHANISM OF RESPONSE TO NOVEL HPV-SPECIFIC VIRAL IMMUNE THERAPY IN HPV ASSOCIATED HEAD AND NECK CANCER" was provided by the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121). The $451,000 award supports research conducted by the University of Chicago to develop and evaluate a novel immunotherapy platform called HB-200, which uses attenuated...
- This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) provides $515,812 to The Johns Hopkins University to study the progression of HPV-related oropharynx cancer (HPV-OPC) and how it differs between individuals with and without HIV. The study aims to: 1) characterize the impact of HIV on oral HPV16 persistence, 2) evaluate the performance of oral and blood biomarkers for...
- This Project Grant award was provided by the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) federal grant program, to the University of Arizona. The $128,126 award, granted on December 1, 2024, supports research investigating how human papillomavirus (HPV) infection may evade the body's innate immune response by disrupting the cGAS/STING pathway, which is critical for antiviral and antitumor immunity. The project...
- This federal Project Grant award of $483,360.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will fund research to target vulnerabilities in the EGFR/HER3/HER2 oncogenic signaling circuitry for developing new precision therapies for oral cancer. The project aims to explore synthetic lethal and gene interaction networks to expose druggable systems vulnerabilities and uncover mechanisms of...
- The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $219,660 Project Grant to the Regents of the University of Michigan to conduct research on "Intercepting the Evolution of Pro-Tumoral Myeloid Cells During the Initiation of Oral Cancer". This project aims to investigate how myeloid cells in precancerous lesions develop suppressive phenotypes that inhibit anti-tumor immune...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $141,762 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to a collaborative research partnership between Henry Ford Health and Michigan State University Health Sciences. The project aims to investigate the mechanism by which the E3 ubiquitin ligase MARCHF8 promotes immune evasion in human papillomavirus (HPV)-positive head and neck squamous cell carcinomas (HNSCC) by directing the...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,768 to the University of New Mexico to conduct research focused on understanding the fundamental biological mechanisms of human papillomavirus (HPV)-induced tumors and precancerous lesions. The award aims to elucidate how inhibition of the MEK/ERK signaling pathway can lead to regression of HPV-driven tumors, with the goal of advancing scientific knowledge that can enable improved...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Case Western Reserve University provides $510,650.00 in funding to investigate the biological factors driving clinical outcomes in HPV-positive oropharyngeal cancer (OPSCC). The research leverages a large cohort of 562 OPSCC patients from the Cleveland area, including 74 individuals from a high-risk subgroup, to explore how factors like HPV status, HPV genotype, and the tumor-immune...